UK markets closed
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • FTSE 250

    20,961.31
    -334.92 (-1.57%)
     
  • AIM

    1,163.26
    -10.13 (-0.86%)
     
  • GBP/EUR

    1.1617
    +0.0020 (+0.17%)
     
  • GBP/USD

    1.3827
    -0.0067 (-0.48%)
     
  • BTC-GBP

    35,196.54
    +1,348.41 (+3.98%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • DOW

    31,496.30
    +572.16 (+1.85%)
     
  • CRUDE OIL

    66.28
    +2.45 (+3.84%)
     
  • GOLD FUTURES

    1,698.20
    -2.50 (-0.15%)
     
  • NIKKEI 225

    28,864.32
    -65.78 (-0.23%)
     
  • HANG SENG

    29,098.29
    -138.50 (-0.47%)
     
  • DAX

    13,920.69
    -135.65 (-0.97%)
     
  • CAC 40

    5,782.65
    -48.00 (-0.82%)
     

Receipt of a CRL Slows Approval, Causing Increased Costs and Lost Sales, and May Prompt Withdrawal - ResearchAndMarkets.com

·2-min read

The "Trends: Hot Topic Catalyst" report has been added to ResearchAndMarkets.com's offering.

Receipt of a CRL slows approval, causing increased costs and lost sales, and may prompt withdrawal. The FDA Amendments Act (FDAAA) provided the FDA with new powers in relation to drug safety, including the authority to impose postmarketing requirements (PMRs) and Risk

Evaluation and Mitigation Strategies (REMS) on drug manufacturers, which took effect on March 25, 2008. The FDAAA has increased the costs of drug development due to a rise in post-approval spending: the average number of PMRs issued per drug was four in 2011 compared to two in 2008.

Complex REMS, which are issued relatively infrequently, require a significant investment from the applicant compared to REMS that only require medication guides and/or communication plans, and the impact on drug sales is almost certainly negative.

Key Topics Covered:

EXECUTIVE SUMMARY

  • Overview of US drug approval regulations and procedures

  • Complete Response Letters and impact on approval

  • Take-home messages to avoid Complete Response Letters

REGULATIONS AND PROCEDURES OF RELEVANCE TO COMPLETE RESPONSE LETTERS

  • The FDA regulatory burden is increasing

  • US drug submissions process

  • References

COMPLETE RESPONSE LETTERS AND IMPACT ON APPROVAL

  • Trends in Complete Response Letters

  • FDA advisory committee meetings and Complete Response Letters

  • References

TAKE-HOME MESSAGES TO AVOID COMPLETE RESPONSE LETTERS

  • Common deficiencies that trigger a Complete Response Letter

  • Case studies

  • Neutroval (tbo-filgrastim)

  • Bydureon (exenatide)

  • Nucynta ER (tapentadol)

  • Lamictal (lamotrigine)

  • Menveo (meningococcal ACWY vaccine)

  • Horizant (gabapentin enacarbil)

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/fv5pvu

View source version on businesswire.com: https://www.businesswire.com/news/home/20210127005786/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900